Celularity Inc. (CELU)
NASDAQ: CELU · IEX Real-Time Price · USD
3.020
-0.010 (-0.33%)
At close: May 1, 2024, 4:00 PM
3.000
-0.020 (-0.66%)
After-hours: May 1, 2024, 4:59 PM EDT
Celularity Revenue
Celularity had revenue of $14.79M in the twelve months ending September 30, 2023, down -20.93% year-over-year. Revenue in the quarter ending September 30, 2023 was $3.79M, a -8.44% decrease year-over-year. In the year 2022, Celularity had annual revenue of $17.98M, a decrease of -15.75%.
Revenue (ttm)
$14.79M
Revenue Growth
-20.93%
P/S Ratio
4.45
Revenue / Employee
$65,724
Employees
225
Market Cap
65.78M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 17.98M | -3.36M | -15.75% |
Dec 31, 2021 | 21.34M | 7.06M | 49.43% |
Dec 31, 2020 | 14.28M | -6.87M | -32.48% |
Dec 31, 2019 | 21.15M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCELU News
- 9 days ago - Celularity Inc. to Host Investor and Analyst Research & Development Day - GlobeNewsWire
- 12 days ago - Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing - GlobeNewsWire
- 13 days ago - Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024 - GlobeNewsWire
- 16 days ago - Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products - GlobeNewsWire
- 23 days ago - Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells - GlobeNewsWire
- 5 weeks ago - Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L - GlobeNewsWire
- 6 weeks ago - Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy - GlobeNewsWire
- 6 weeks ago - Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit - GlobeNewsWire